[go: up one dir, main page]

WO2015066439A3 - Methods of treating hematological malignancies - Google Patents

Methods of treating hematological malignancies Download PDF

Info

Publication number
WO2015066439A3
WO2015066439A3 PCT/US2014/063367 US2014063367W WO2015066439A3 WO 2015066439 A3 WO2015066439 A3 WO 2015066439A3 US 2014063367 W US2014063367 W US 2014063367W WO 2015066439 A3 WO2015066439 A3 WO 2015066439A3
Authority
WO
WIPO (PCT)
Prior art keywords
hematological malignancies
methods
treating hematological
treating
activating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/063367
Other languages
French (fr)
Other versions
WO2015066439A8 (en
WO2015066439A2 (en
Inventor
Matthew J. HAWRYLUK
Jie He
Vincent A. MILLER
Philip James STEPHENS
Omar Abdel-Wahab
Jeffrey R. GARDNER
Ross LEVINE
Marcel Van Den Brink
Andrew ZELENETZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Foundation Medicine Inc
Original Assignee
Memorial Sloan Kettering Cancer Center
Foundation Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center, Foundation Medicine Inc filed Critical Memorial Sloan Kettering Cancer Center
Publication of WO2015066439A2 publication Critical patent/WO2015066439A2/en
Publication of WO2015066439A8 publication Critical patent/WO2015066439A8/en
Publication of WO2015066439A3 publication Critical patent/WO2015066439A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Drying Of Semiconductors (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods and compositions for treating and detecting hematological malignancies are disclosed. The invention is based, at least in part, on the discovery of alterations, e.g., activating mutations, not previously identified in hematological malignancies, such as Chronic Lymphocytic Leukemia (CLL). In certain embodiments, the alteration includes an activating mutation in a MAP kinase (Mitogen-activated Qrotein kinase or MAPK) pathway gene or gene product, e.g., an activating mutation in BRAF and/or KRAS (also referred to herein as "B-Raf and "K-Ras," respectively).
PCT/US2014/063367 2013-11-01 2014-10-31 Methods of treating hematological malignancies Ceased WO2015066439A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361898818P 2013-11-01 2013-11-01
US61/898,818 2013-11-01

Publications (3)

Publication Number Publication Date
WO2015066439A2 WO2015066439A2 (en) 2015-05-07
WO2015066439A8 WO2015066439A8 (en) 2015-06-25
WO2015066439A3 true WO2015066439A3 (en) 2015-11-05

Family

ID=53005385

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/063367 Ceased WO2015066439A2 (en) 2013-11-01 2014-10-31 Methods of treating hematological malignancies

Country Status (1)

Country Link
WO (1) WO2015066439A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105560217B (en) * 2016-03-01 2019-03-01 周斌 Application of the honokiol in acute myelocytic leukemia
MX393780B (en) 2017-01-17 2025-03-24 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006053201A2 (en) * 2004-11-09 2006-05-18 Mount Sinai School Of Medicine Of New York University Treatment of cancer by simultaneous inhibition of b-raf and restoration or mimicry of p16 ink4a activity
WO2010062705A1 (en) * 2008-11-03 2010-06-03 Quest Diagnostics Investments Incorporated Cancer diagnosis using ki-67
WO2012061683A2 (en) * 2010-11-05 2012-05-10 Glaxosmithkline Llc Methods for treating cancer
US8293726B2 (en) * 2005-12-02 2012-10-23 Vianova Labs, Inc. Treatment of cancer and other diseases
WO2013001372A2 (en) * 2011-06-30 2013-01-03 University Of Oslo Methods and compositions for inhibition of activation of regulatory t cells
WO2014071419A2 (en) * 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006053201A2 (en) * 2004-11-09 2006-05-18 Mount Sinai School Of Medicine Of New York University Treatment of cancer by simultaneous inhibition of b-raf and restoration or mimicry of p16 ink4a activity
US8293726B2 (en) * 2005-12-02 2012-10-23 Vianova Labs, Inc. Treatment of cancer and other diseases
WO2010062705A1 (en) * 2008-11-03 2010-06-03 Quest Diagnostics Investments Incorporated Cancer diagnosis using ki-67
WO2012061683A2 (en) * 2010-11-05 2012-05-10 Glaxosmithkline Llc Methods for treating cancer
WO2013001372A2 (en) * 2011-06-30 2013-01-03 University Of Oslo Methods and compositions for inhibition of activation of regulatory t cells
WO2014071419A2 (en) * 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof

Also Published As

Publication number Publication date
WO2015066439A8 (en) 2015-06-25
WO2015066439A2 (en) 2015-05-07

Similar Documents

Publication Publication Date Title
MX2025006476A (en) Compositions and methods for immunooncology
FR2985274B1 (en) FIBROUS STRUCTURES INCLUDING PARTICLES AND THEIR MANUFACTURING PROCESS
EP3892316A3 (en) Cell separation devices, systems, and methods
EP4545544A3 (en) Modified crispr rna and modified single crispr rna and uses thereof
MD3237423T2 (en) Thieno[2,3-c]pyrrol-4-one derivatives as ERK inhibitors
NZ718190A (en) Substituted quinazolines for inhibiting kinase activity
EP4324930A3 (en) Compositions and methods for peronospora resistance in spinach
UA117470C2 (en) Substituted xanthines and methods of use thereof
PH12015502041B1 (en) Heteroaryl compounds and uses thereof
MX340756B (en) Quinazoline compounds as serine/threonine kinase inhibitors.
PH12017501822A1 (en) Quinoline derivatives as tam rtk inhibitors
PH12018501463B1 (en) Pyrimidinyl tyrosine kinase inhibitors
MX2021011946A (en) C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency.
EP3356470B8 (en) Polycarbonate-polysiloxane copolymer compositions, articles formed therefrom, and methods of manufacture thereof
EA201391114A1 (en) METHODS OF USE ALK-INHIBITORS
MY186911A (en) Boronic acid derivatives
MX2017004037A (en) Boronic acid derivatives.
WO2017132746A8 (en) Ubiquitin variants and uses thereof as 53bp1 inhibitors
MX2017004043A (en) Boronic acid derivatives.
PH12015501047A1 (en) Use of aqueous polymer dispersion in coating agents for improving colour retention
MX2017004046A (en) Boronic acid derivatives.
MX2014012164A (en) Compositions containing probiotics and a bee pollen/clay complex, preparation method thereof and uses of same in nutrition and therapeutics.
PH12015502757A1 (en) Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
WO2015066439A3 (en) Methods of treating hematological malignancies
MY188108A (en) Heavily phosphor loaded led packages

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14856960

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14856960

Country of ref document: EP

Kind code of ref document: A2